MDM2 and cancer: Y. K. Zhou et al. successfully identified a self-assembled D-peptide supramolecular nanomedicine (NMTP-5) targeting NRP1 and MDM2 using a structure-based virtual screening technique, which self-assembled into nanofibers in an aqueous solution, and after entering the cytoplasm of cancer cells by targeting NRP1, NMTP-5 activated the p53 signaling and induced cell death in vivo by interfering with the MDM2-p53 interaction.